Search results
Results from the WOW.Com Content Network
Necrobiosis lipoidica is a rare, chronic skin condition predominantly associated with diabetes mellitus (known as necrobiosis lipoidica diabeticorum or NLD). [1] It can also occur in individuals with rheumatoid arthritis or without any underlying conditions (). [2]
Lipodystrophy syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue. [ 1 ] [ 2 ] The medical condition is characterized by abnormal or degenerative conditions of the body's adipose tissue .
Common adverse effects include diarrhea, nausea, and abdominal pain. [16] It has a small risk of causing low blood sugar. [16] High blood lactic acid level is a concern if the medication is used in overly large doses or prescribed in people with severe kidney problems. [23] [24] Metformin is a biguanide anti-hyperglycemic agent. [16]
Acquired generalized lipodystrophy (AGL), also known as Lawrence syndrome [1] and Lawrence–Seip syndrome, [1] is a rare skin condition that appears during childhood or adolescence, characterized by fat loss affecting large areas of the body, particularly the face, arms, and legs.
Wall & Melzack's Textbook of Pain is a medical textbook published by Elsevier. It is named after Patrick David Wall and Ronald Melzack, who introduced the gate control theory into pain research in the 1960s. First released in 1984, the book has been described as "the most comprehensive scientific reference text in the field of pain medicine". [1]
Yes, metformin treatment has been shown to lower risk of heart-related events in people with type 2 diabetes by improving blood fat levels, reducing inflammation, and lowering blood pressure ...
Congenital generalized lipodystrophy (also known as Berardinelli–Seip lipodystrophy) is an extremely rare autosomal recessive condition, characterized by an extreme scarcity of fat in the subcutaneous tissues. [2] It is a type of lipodystrophy disorder where the magnitude of fat loss determines the severity of metabolic complications. [3]
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...